



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2019

The amyloid- degradation intermediate A 34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease

Kirabali, Tunahan ; Rigotti, Serena ; Siccoli, Alessandro ; Liebsch, Filip ; Shobo, Adeola ; Hock, Christoph ; Nitsch, Roger M ; Multhaup, Gerhard ; Kulic, Luka

Abstract: An impairment of amyloid -peptide (A) clearance is suggested to play a key role in the pathogenesis of sporadic Alzheimer's disease (AD). Amyloid degradation is mediated by various mechanisms including fragmentation by enzymes like neprilysin, matrix metalloproteinases (MMPs) and a recently identified amyloidolytic activity of -site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 cleavage of A 40 and A 42 results in the formation of a common A 34 intermediate which was found elevated in cerebrospinal fluid levels of patients at the earliest disease stages. To further investigate the role of A 34 as a marker for amyloid clearance in AD, we performed a systematic and comprehensive analysis of A 34 immunoreactivity in hippocampal and cortical post-mortem brain tissue from AD patients and non-demented elderly individuals. In early Braak stages, A 34 was predominantly detectable in a subset of brain capillaries associated with pericytes, while in later disease stages, in clinically diagnosed AD, this pericyte-associated A 34 immunoreactivity was largely lost. A 34 was also detected in isolated human cortical microvessels associated with brain pericytes and its levels correlated with A 40, but not with A 42 levels. Moreover, a significantly decreased A 34/A 40 ratio was observed in microvessels from AD patients in comparison to non-demented controls suggesting a reduced proteolytic degradation of A 40 to A 34 in AD. In line with the hypothesis that pericytes at the neurovascular unit are major producers of A 34, biochemical studies in cultured human primary pericytes revealed a time and dose dependent increase of A 34 levels upon treatment with recombinant A 40 peptides while A 34 production was impaired when A 40 uptake was reduced or BACE1 activity was inhibited. Collectively, our findings indicate that A 34 is generated by a novel BACE1-mediated A clearance pathway in pericytes of brain capillaries. As amyloid clearance is significantly reduced in AD, impairment of this pathway might be a major driver of the pathogenesis in sporadic AD.

DOI: <https://doi.org/10.1186/s40478-019-0846-8>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-180826>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:

Kirabali, Tunahan; Rigotti, Serena; Siccoli, Alessandro; Liebsch, Filip; Shobo, Adeola; Hock, Christoph; Nitsch, Roger M; Multhaup, Gerhard; Kulic, Luka (2019). The amyloid- degradation intermediate A 34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease. *Acta Neuropathologica Communications*, 7:194.
DOI: <https://doi.org/10.1186/s40478-019-0846-8>

RESEARCH

Open Access



The amyloid- β degradation intermediate A β 34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease

Tunahan Kirabali¹ , Serena Rigotti¹, Alessandro Siccoli¹, Filip Liebsch^{2,3}, Adeola Shobo³, Christoph Hock^{1,4}, Roger M. Nitsch^{1,4}, Gerhard Multhaup³ and Luka Kulic^{1,5*}

Abstract

An impairment of amyloid β -peptide (A β) clearance is suggested to play a key role in the pathogenesis of sporadic Alzheimer's disease (AD). Amyloid degradation is mediated by various mechanisms including fragmentation by enzymes like neprilysin, matrix metalloproteinases (MMPs) and a recently identified amyloidolytic activity of β -site amyloid precursor protein cleaving enzyme 1 (BACE1). BACE1 cleavage of A β 40 and A β 42 results in the formation of a common A β 34 intermediate which was found elevated in cerebrospinal fluid levels of patients at the earliest disease stages. To further investigate the role of A β 34 as a marker for amyloid clearance in AD, we performed a systematic and comprehensive analysis of A β 34 immunoreactivity in hippocampal and cortical post-mortem brain tissue from AD patients and non-demented elderly individuals. In early Braak stages, A β 34 was predominantly detectable in a subset of brain capillaries associated with pericytes, while in later disease stages, in clinically diagnosed AD, this pericyte-associated A β 34 immunoreactivity was largely lost. A β 34 was also detected in isolated human cortical microvessels associated with brain pericytes and its levels correlated with A β 40, but not with A β 42 levels. Moreover, a significantly decreased A β 34/A β 40 ratio was observed in microvessels from AD patients in comparison to non-demented controls suggesting a reduced proteolytic degradation of A β 40 to A β 34 in AD. In line with the hypothesis that pericytes at the neurovascular unit are major producers of A β 34, biochemical studies in cultured human primary pericytes revealed a time and dose dependent increase of A β 34 levels upon treatment with recombinant A β 40 peptides while A β 34 production was impaired when A β 40 uptake was reduced or BACE1 activity was inhibited. Collectively, our findings indicate that A β 34 is generated by a novel BACE1-mediated A β clearance pathway in pericytes of brain capillaries. As amyloid clearance is significantly reduced in AD, impairment of this pathway might be a major driver of the pathogenesis in sporadic AD.

Keywords: Alzheimer's disease, Pericyte, A β 34, Amyloid clearance

Introduction

Amyloid beta (A β) plaques with extracellular fibrillar deposits of A β peptide and neurofibrillary tangles (NFTs) composed of phosphorylated tau represent the key histopathological hallmarks of Alzheimer's disease [22, 33, 58].

A β peptides are generated via sequential proteolytic cleavage of the amyloid precursor protein (APP) [47]. Initial cleavage of APP by β -secretase generates a membrane-bound C-terminal fragment of APP (β -CTF) [14, 66] which is sequentially processed by γ -secretase resulting in the formation of longer species, like A β 40 and A β 42/43, in addition to several other C-terminally truncated A β variants [39, 56]. A full set of A β isoforms with both N- and C-terminally truncated A β species can be detected in the human brain and cerebrospinal fluid (CSF) [28, 41, 42, 45, 62]. N-terminally truncated A β isoforms show an

* Correspondence: luka.kulic@irem.uzh.ch

¹Institute for Regenerative Medicine, University of Zurich, 8952 Schlieren, Switzerland

⁵F. Hoffmann-La Roche Ltd., Roche Pharma Research & Early Development, 4070 Basel, Switzerland

Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

increased aggregation propensity and have previously been associated with the deposition of dense-core amyloid plaques in the brain [18, 35, 40, 46, 49, 51]. In contrast, C-terminally truncated shorter A β isoforms show a higher solubility in vitro and are more commonly detected in the cerebral vasculature [11, 18, 28, 43]. One of the C-terminally truncated isoforms, A β 34, can be generated as an intermediate of multiple degradation pathways including A β degradation by the matrix metalloproteases (MMP), MMP2 and MMP9 [25], as well as stepwise proteolytic cleavage of both A β 40 and A β 42 by γ -secretase [39]. In addition to its role as the major β -secretase in APP processing, BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) has been shown to cleave longer A β isoforms at position 34 and this pathway has been identified as the major source of A β 34 [19, 50]. This additional BACE1 mediated cleavage can only take place with A β peptides as substrates implying that BACE1 indeed acts as an A β 40/42 degrading enzyme to generate A β 34 [19, 50]. In a recent study, we were able to show that A β 34 levels are directly affected by over-expression or inhibition of BACE1 both in vitro and in vivo, and that cerebral BACE1 is the critical factor for A β 34 generation [30]. Supporting its proposed role as a biomarker for clearance in sporadic AD, CSF A β 34 levels were found to be elevated in subjects with mild cognitive impairment (MCI) who later converted to AD dementia [30]. Moreover, we also discovered a positive correlation between CSF A β 34 levels and overall A β clearance rates in individuals with biomarker evidence of cerebral amyloid deposition [30].

In the present study, we investigated the tissue distribution of the C-terminally truncated isoform A β 34 in post-mortem brain samples from healthy elderly individuals and AD patients of various AD neuropathological stages according to Braak [8, 9]. A β 34 immunoreactivity was detected exclusively in the vasculature and was most prominent in brain capillaries of healthy elderly individuals in the early Braak stages. In AD patients and more advanced Braak stages, however, this capillary associated A β 34 immunoreactivity was largely lost. Colocalization studies in postmortem brain tissue and isolated human microvessels revealed a unique association of A β 34 with the platelet derived growth factor receptor beta (PDGFR- β) which serves as a marker for brain pericytes [1, 31]. Further in vitro biochemical studies in cultured human primary pericytes confirmed that the C-terminally truncated isoform A β 34 is released by these cells via BACE1 mediated enzymatic cleavage of A β 40. Collectively, the results of our work suggest the existence of a novel pericyte mediated A β clearance pathway, which generates A β 34 as a stable intermediate. Early impairment of this pathway may contribute to the overall reduced A β clearance associated with sporadic AD [34].

Materials and methods

Post-mortem human samples

Paraffin-embedded hippocampus and middle-frontal cortex (gyrus frontalis medius) tissue blocks and frozen middle frontal cortex samples were provided by the Netherlands Brain Bank (NBB), the Netherlands Institute for Neuroscience, Amsterdam, the Netherlands. Post-mortem samples were collected from donors with a written informed consent for a brain autopsy and the use of the material for research purposes was obtained by the NBB. Subjects' demographics, neuropathological and clinical evaluations are listed in Table 1. In brief, subjects are classified according to their Braak stages from stage I to VI [8, 9]. Age, gender, apolipoprotein E (APOE) genotype, CERAD (Consortium to Establish a Registry for Alzheimer's Disease) score for amyloid load and clinical diagnosis (non-demented control (NDCNTRL) or AD patient (AD)) are provided for each subject [27, 36].

Immunofluorescence staining

Sections of paraffin-embedded hippocampus and cortex samples with 5 μ m thickness were deparaffinized in xylene and then rehydrated by immersing the slides in order in 100% ethanol, 95% ethanol, 70% ethanol and water. Sections were pretreated by boiling in 0.1 M sodium citrate buffer for antigen retrieval as previously described [20]. Only for amyloid plaque staining, sections were also incubated in 95% formic acid for 5 min prior to citrate buffer pre-treatment. Unspecific binding sites were blocked with 10% horse serum in phosphate-buffered saline (PBS) with 0.2% Triton X-100 (PBS-T). After blocking, sections were incubated overnight at 4 °C with primary antibodies diluted in 5% horse serum in PBS-T. All primary antibodies and dilutions used in immunohistochemistry are listed in Additional file 1. After washing with PBS, sections were incubated for 2 h at room temperature with secondary antibodies (1:200 dilution in 5% horse serum in PBS-T, donkey anti-mouse/rabbit/goat conjugated to Alexa488, Cy3, Alexa647 and streptavidin conjugated to Alexa488) purchased from Jackson ImmunoResearch (Pennsylvania, USA). Following the secondary antibody step, sections were incubated for 10 min with 2 mg/ml DAPI (4',6-diamidino-2-phenylindole) (Sigma Aldrich, Missouri, USA) in PBS for nucleus staining and for 5 min in 0.2% Sudan Black (Sigma Aldrich) in 70% ethanol to quench auto-fluorescence [38]. Coverslips were mounted with water based mounting medium and slides were stored at 4 °C. Pictures were taken with Leica DM4000B microscope or Leica TCS SP8 confocal microscope. For peptide blocking/competition assay, 1 μ g anti-A β 34 and 1 μ g anti-PDGFR- β antibodies were pre-incubated with 10 μ g recombinant human A β 34 peptide (Anaspec, California, USA) in 5%

Table 1 Characteristics of post-mortem human brain samples

Brain Region: Hippocampus (paraffin-embedded)						
Braak Stage	Number of Subjects	Age at Death ^a	Gender ^b	APOE4 Status ^c	CERAD Score ^d	Diagnosis ^e
I	6	79 ± 6.8	M (1) F (5)	+ (1), – (2)	O(2), A(2), B(2)	NDCNTRL
II	6	85.7 ± 1.8	M (1) F (5)	+ (2), – (4)	A(1), B(3), C(2)	NDCNTRL
III	6	82 ± 5.8	M (5) F (1)	+ (3), – (2)	A(1), B(2), C(3)	NDCNTRL
IV	7	92.3 ± 3.3	M (1) F (6)	+ (2), – (5)	C	NDCNTRL (2), AD(5)
V	4	82.3 ± 10.1	M (0) F (4)	+ (3), – (1)	C	AD
VI	6	86 ± 6.8	M (0) F (6)	+ (4), – (2)	C	AD
Brain Region: Cortex (paraffin-embedded)						
Braak Stage	Number of Subjects	Age at Death	Gender	APOE4 Status	CERAD Score	Diagnosis
I	4	82.5 ± 9.3	M (2) F (2)	+ (0), – (4)	A(1), B(2), C(1)	NDCNTRL
II	3	85.3 ± 0.5	M (1) F (2)	+ (1), – (2)	A(1), B(3), C(2)	NDCNTRL
III	4	87 ± 3.7	M (3) F (1)	+ (2), – (2)	A(1), B(2), C(3)	NDCNTRL
IV	6	89.3 ± 5.4	M (2) F (4)	+ (3), – (3)	B(2), C(4)	NDCNTRL (2), AD (4)
V	3	84.3 ± 13.2	M (0) F (3)	+ (2), – (1)	C	AD
VI	5	89.2 ± 3.4	M (0) F (5)	+ (4), – (1)	C	AD
Brain Region: Cortex (frozen)						
Braak Stage	Number of Subjects	Age at Death	Gender	APOE4 Status	CERAD Score	Diagnosis
I – II	4	88.7 ± 7.9	M (0) F (4)	+ (0), – (2)	O(1), A(1), B(1), C(1)	NDCNTRL
III – IV	5	91.4 ± 2.9	M (1) F (4)	+ (1), – (2)	O(1), B(2), C(2)	NDCNTRL (3), AD (2)
V – VI	5	75.2 ± 8.1	M (2) F (3)	+ (2), – (2)	B(1), C(4)	AD

^a Age at death is reported as mean ± standard deviation^b M Male, F Female^c APOE4 Status +: APOE3/4 or APOE4/4, –: APOE3/3, APOE3/2, APOE2/2. APOE4 status were not available for some subjects^d CERAD Consortium to Establish a Registry for Alzheimer's Disease^e NDCNTRL Non-demented control, AD Alzheimer's disease patient

horse serum in PBS-T for 1 h. The immunohistochemistry protocol was then followed as described above.

Quantification of immunofluorescence staining

For each subject, 2 sections, which are at least 50 µm apart from each other, were used and 10 pictures with 20X magnification were randomly taken per section. For Aβ34 and PDGFR-β quantitative analyses, sections were also stained with anti-Collagen IV antibody to allow a quantification of the total number of vessels in each visual field. Vessels with Aβ34 or PDGFR-β immunoreactivity were counted manually and divided by the total number of vessels in the visual field assessed by Collagen IV immunostaining. In order to quantify only capillaries, vessels with a diameter > 10 µm were excluded. Mean of 20 visual fields were calculated for each subject and results were reported as percentage of Aβ34 or PDGFR-β positive vessels. For tau tangle and amyloid plaque quantifications, pictures were converted to 8-bit images and constant thresholds were applied to each picture. Intra-neuronal APP signal was also eliminated by using this threshold in amyloid plaque quantification. The area for each immunostained picture was calculated with ImageJ and results were reported as percentage of amyloid or

tau positive area. Mean of 20 visual fields were calculated for each subject and reported in the figures.

Microvessel isolation and preparation of vessel enriched brain lysates

Previously published microvessel isolation protocols for mouse and rat brains were adapted for frozen human brains [6, 10, 65]. Briefly, 1 g frozen human cortex was placed in 5 ml Hank's balanced salt solution (HBSS) with protease and phosphatase inhibitors and homogenized with glass Teflon homogenizer (20 strokes at 400 rpm). Homogenates were centrifuged at 2000 g for 10 min at 4 °C. The pellet was resuspended in 17.5% Dextran (Sigma Aldrich) in PBS and centrifuged at 4400 g for 15 min at 4 °C. The pellet was again resuspended in 1 ml HBSS and passed through filters with 100 µm and 20 µm pore size (Pluriselect Life Science, Leipzig, Germany) in the respective order. The material retained on the 20 µm filter was collected by gentle washing with HBSS and centrifuged at 2000 g for 10 min at 4 °C. The resulting pellet (corresponding to microvessels) was resuspended in 4% paraformaldehyde (PFA) in PBS for fixation. Similar to the immunofluorescence protocol, microvessels were blocked with 10% horse serum in PBS-T and

incubated 2 h with primary antibodies and 2 h with secondary antibodies in PCR tubes at room temperature. Microvessels were then placed on glass slides and coverslips were mounted with water-based mounting medium. Images were taken with Leica TCS SP8 confocal microscope. For vessel enriched brain lysates, material retained on both filters was collected and combined by washing with HBSS and centrifugation at 2000 g for 10 min at 4 °C. After centrifugation, the pellet was incubated in RIPA buffer at 4 °C with rotation for 1 h, sonicated for 5 min in ultrasonic bath and then centrifuged at 10000 g for 15 min at 4 °C. Supernatants were collected and stored at -80 °C.

Immunoassays

Custom-made 4-plex (A β 34, A β 38, A β 40, and A β 42) meso scale discovery (MSD) plates were purchased from Meso Scale Diagnostics (Maryland, USA). For 1-plex A β 34 assay, high binding MSD plates were spot-coated with monoclonal anti-A β 34 antibody and incubated overnight. The assay was performed according to manufacturer's instructions as previously reported [30]. Briefly, diluent 35 was added into each well and incubated for 1 h at room temperature for blocking. PBS with 0.2% Tween-20 was used for washing. 25 μ l sample or standard and 25 μ l sulfo-tag anti-amyloid beta (6E10 or 4G8) detection antibody were added. Plates were incubated at 4 °C overnight with rigorous shaking. On the following day, 2X read buffer was added after washing and plates were read with SECTOR Imager 600 plate reader (Meso Scale Diagnostics, USA) and analyzed with MSD Workbench software (Meso Scale Diagnostics, USA).

The human total PDGFR- β enzyme-linked immunosorbent assay (ELISA) and ELISA ancillary reagent kits were purchased from R&D Systems (Minnesota, USA). The assay was performed according manufacturer's instructions. Briefly, plates were incubated with capture antibody diluted in PBS overnight at 4 °C. PBS with 0.2% Tween-20 was used for washing. Aliquots of 100 μ l sample or standard were diluted in diluent 12 and incubated for 2 h at room temperature. After washing, biotinylated detection antibody, diluted in diluent 14, was added into wells and incubated for 2 h at room temperature. Following a wash step, streptavidin-horseradish peroxidase (HRP) substrate diluted in diluent 14 was added. Color reagents were added and incubated for 20 min; the reaction was stopped by adding stop solution (2 N sulfuric acid) and absorbance at 520 nm was measured with Tecan Infinite M Nano plate reader.

Cell culture

Human primary pericytes were purchased from ScienCell (California, USA). Cells were maintained in Pericyte

Medium (ScienCell) with addition of 2% fetal bovine serum (FBS) (ScienCell), penicillin/streptomycin (ScienCell) and pericyte growth supplement (ScienCell) in poly-L-lysine (ScienceCell or SigmaAldrich) coated T75 flasks. Cells from each passage were frozen in 10% dimethyl sulfoxide (DMSO) in FBS and stored at -150 °C. Cells from passage 3 to 6 were used in experiments.

For A β uptake assays, human recombinant A β 40 (rPeptide, Watkinsville, USA) and mouse A β 40 synthetic peptides (Anaspec, California, USA) were prepared according to published protocols [52]. Briefly, lyophilized peptides were dissolved in hexafluoro-2-propanol (HFIP) on ice and aliquoted into 1.5 ml Eppendorf tubes. Aliquots were lyophilized and stored at -80 °C. Before the experiment, lyophilized peptide was dissolved in DMSO and concentration adjusted with pericyte medium. Pericytes were cultured in either 60-mm dishes or 6-well plates and treated with different concentrations of A β 40 for varying incubation times. At the end of the experiment cell lysates were prepared in RIPA buffer, cell media were collected and stored for further analysis. In order to block A β uptake, cells were treated with 10 μ M endocytosis blocker IPA3 (1,1'-Dithiodi-2-naphthol) (Abcam, Cambridge, United Kingdom) or 500 nM low density lipoprotein receptor-related protein 1 (LRP1) blocker RAP (receptor associated protein) (R&D Systems) for 2 h prior to A β 40 (2 μ M) addition. Solutions of 10 μ M IPA3 and 500 nM RAP were used since these concentrations were reported to reduce A β 40 uptake without affecting cell viability [61]. Cell lysates were prepared with RIPA buffer, cell media were collected and stored for further analysis. In order to study A β uptake, pericytes were seeded on coverslips in a 24-well plate and incubated with Hilyte Fluor 488-labeled human A β 40 (Anaspec) after RAP or IPA3 treatment. After fixation and DAPI staining, cells were imaged with Leica TCS SP8 confocal microscope. For 96-well assay, pericytes were plated in 96-wells and incubated with Hilyte Fluor 488-labeled human A β 40 after RAP or IPA3 treatment. After washing, extracellular A β was quenched with 0.2% trypan blue fluorescence and measured at 485 nm excitation and 535 nm emission wavelength for detection of Hilyte Fluor-488 with Tecan Spark plate reader. Subsequently, cells were incubated with DAPI and fluorescence was measured with 360 nm excitation and 485 nm emission wavelength to normalize Hilyte Fluor 488 fluorescence for cell count in each well. For BACE1 inhibition assays, pericytes were treated with varying concentrations (10 μ M, 5 μ M, 2 μ M, 1 μ M) of BACE1 Inhibitor IV (Sigma Aldrich) for 12 h prior to A β 40 (2 μ M) addition. As in previous experiments, lysates were prepared with RIPA buffer, cell media were collected and stored for further analysis.

Immunocytochemistry

Coverslips were coated with poly-L-lysine and placed in 24-well plate. Cells were seeded in 24-well plates, incubated overnight and then fixed with 4% PFA in PBS. Unspecific binding was blocked with 10% horse serum in PBS. Cells were incubated with primary antibody for 2 h, followed by secondary antibody for 90 min at room temperature (Additional file 1). For nucleus staining, cells were incubated with 2 mg/ml DAPI solution in distilled water for 10 min. Then, coverslips were transferred on slides with water-based mounting medium. Cells were imaged with Leica DM4000B microscope or Leica TCS SP8 confocal microscope.

Western blot and immunoprecipitation

Pericyte lysates were mixed with 2X Novex SDS sample buffer (Thermo Fisher Scientific, Massachusetts, USA) containing 10% β -mercaptoethanol 1:1, incubated at 95 °C for 5 min and loaded on Novex 10–20% Tricine gel (Thermo Fisher Scientific). Electrophoresis was performed at 100 V for 2 h in Tricine running buffer. After transfer, nitrocellulose membranes were blocked with 5% milk blocking solution and incubated with primary antibodies at 4 °C overnight. On the next day, membranes were incubated with HRP-coupled secondary antibodies (Jackson ImmunoResearch) diluted in 5% milk blocking solution for 2 h at room temperature and developed with SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher). Images were taken with ImageQuant LAS 400 (GE Healthcare, Illinois, USA). BACE1 immunoprecipitation was performed using magnetic separation with Dynabead M-280 Sheep Anti-Rabbit IgG (Invitrogen) according to the manufacturer's protocol. Briefly, cell lysates were incubated with rabbit anti-BACE1 antibody (ab2077, abcam) overnight at 4 °C with gentle rotation. After addition of magnetic beads, samples were incubated for 1 h with gentle rotation at room temperature. After washing with PBS, beads were magnetically separated and incubated in 2X Novex SDS sample buffer containing 10% β -mercaptoethanol at 95 °C for 5 min. Beads were magnetically separated and proteins loaded on Novex 10–20% Tricine gel. Electrophoresis and Western blotting were performed as described above.

Statistical analysis


Graphpad Prism 8 software was used for all statistical analyses. Assumption of normal (Gaussian) distribution was tested with Shapiro-Wilk normality test ($\alpha = 0.05$). If the assumption of normality was true, the significance of the differences between two groups was tested with a two-tailed unpaired Student's *t* test. The significance of the differences between more than two groups was

tested with 1-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. Correlations were calculated with Pearson's correlation ($\alpha = 0.05$, confidence interval 95%, two tailed). In case of a deviation from normal distribution, the significance of the differences between two groups was tested with a two-tailed unpaired Mann-Whitney test. Correlations were calculated with Spearman's correlation ($\alpha = 0.05$, confidence interval 95%, two tailed). Correlation coefficients (*r*) and *p*-values were reported in the figures.

Results

A β 34 immunoreactivity is detected in brain capillaries of non-demented elderly individuals and this immunoreactivity is progressively reduced in AD patients


In this study, we performed a comprehensive disease-stage dependent immunohistochemical analysis of A β 34 immunoreactivity in hippocampal and cortical brain tissue from cognitively intact elderly individuals and AD patients of various Braak stages (Table 1). Throughout disease stages, A β 34 was predominantly found in small vessels, which were identified as brain capillaries based on their structure and diameter of < 10 μ m (Fig. 1a, Additional file 2a). Notably, these A β 34 positive capillaries were free of fibrillar amyloid (assessed by Thio S staining, Additional file 2b), and capillary congophilic amyloid angiopathy (CAA) was generally absent in the investigated sample. Moreover, A β 34 was not detectable in parenchymal amyloid plaques, but was occasionally observed in colocalization with arterial CAA deposits in a minority of the assessed brain samples (Additional file 2b-c). To further quantitatively assess the predominant A β 34 immunoreactivity in brain capillaries of AD patients and non-demented control individuals, double immunofluorescence staining with the basement membrane marker collagen IV was performed (Fig. 1b). The stainings revealed that in non-demented elderly individuals up to 60–70% of capillaries showed immunoreactivity for A β 34 (Fig. 1d). In contrast, the proportion of A β 34 positive capillaries in patients with AD clinical diagnosis was strongly reduced (Fig. 1d), whereas the capillary density was not significantly changed (Additional file 2d). A disease stage dependent analysis of A β 34 immunoreactivity in the whole sample revealed a peak of A β 34 immunoreactivity in the early Braak stages (highest percentage of A β 34 positive capillaries in Braak stage 2) and a dramatic loss of A β 34 positive vessels between Braak stages 3 and 4 (Fig. 1c). Interestingly, A β 34 immunoreactivity negatively correlated both with amyloid plaque load (Fig. 1e) and with tau pathology (Fig. 1f) in hippocampus and cortex; however, stronger effects were observed for the association of A β 34 with tau (Fig. 1).



Aβ34 in capillaries colocalizes with pericytes which are gradually lost in advanced disease stages

Having shown that Aβ34 in non-demented elderly individuals and in patients with AD was mainly associated with brain capillaries, and that the percentage of Aβ34 immunoreactive vessels was progressively reduced in

advanced AD neuropathological stages, we determined next in more details the exact localization of capillary Aβ34 immunoreactivity within the neurovascular unit. Double immunofluorescence stainings with basement membrane marker Collagen IV (Fig. 2a), astroglial marker glial fibrillary acidic protein (GFAP) (Fig. 2b),



endothelial cell marker CD31 (Fig. 2c) and pericyte marker PDGFR-β (Fig. 2b-c-d) were performed. These analyses demonstrated a robust overlay of Aβ34 immunoreactivity with PDGFR-β, but not with CD31, nor with GFAP, suggesting that Aβ34 was specifically localized in brain pericytes (Fig. 2b-c-d). In line with these findings, a close association was also observed with Collagen IV which represents a major extracellular component of the capillary basement membrane where pericytes reside (Fig. 2a). Given the observed colocalization of Aβ34 immunoreactivity with brain pericytes within the neuro-vascular unit and the above-mentioned disease-stage

dependent loss of Aβ34 positive capillaries in AD, we hypothesized that the progressive decrease in Aβ34 positive capillaries in the course of AD could at least partially be explained by the previously reported dysfunction and loss of brain pericytes in AD pathogenesis [23, 48]. In agreement with this hypothesis, a strong positive correlation could be established between the percentage of Aβ34 positive and PDGFR-β immunoreactive brain capillaries (Fig. 2e). The analysis of PDGFR-β immunoreactivity across Braak stages revealed a gradual loss of pericyte coverage starting already at Braak stage 2 (Fig. 2f). Similar to our results of the quantitative

assessments of A β 34 immunoreactivity, the percentage of PDGFR- β positive capillaries was significantly decreased in AD patients in comparison to non-demented controls both in cortex and hippocampus (Fig. 2g).


A β 34 is present in brain pericytes from isolated human microvessels and its levels are correlated with pericyte marker PDGFR- β in non-demented controls

Collectively, our immunohistochemical findings revealed a predominant localization of A β 34 in brain capillaries and a robust colocalization and strong correlation of A β 34 with pericyte markers. Moreover, we observed a progressive loss of capillary A β 34 immunoreactivity across disease stages which was paralleled by a gradual loss of pericyte coverage. To further investigate the relationship between A β 34 and its longer precursors, A β 40 and A β 42, as well as pericyte markers, microvessels were isolated from frozen cortical samples of healthy non-demented controls and AD patients (Table 1). In line with the results of our immunohistochemical analysis of human postmortem brain tissue, immunofluorescence staining confirmed a colocalization of A β 34 immunoreactivity with pericyte marker PDGFR- β and basement membrane marker Collagen IV in the isolated microvessels (Fig. 3a). Similar to the immunohistochemical findings, quantitative analysis of RIPA-buffer extracted vessel enriched brain lysates demonstrated a significant decrease in total PDGFR- β levels in AD patients in comparison to non-demented controls (Fig. 3b) and a positive correlation between total PDGFR- β and A β 34 levels in non-demented individuals (Fig. 3c). Interestingly, a strong positive correlation was recorded between the levels of vessel-extracted A β 34 and A β 40, but not with A β 42 (Fig. 3d). A significantly decreased A β 34/A β 40 ratio was observed in microvessels from AD patients in comparison to non-demented controls suggesting a reduced proteolytic degradation of A β 40 to A β 34 in AD (Fig. 3e).

Human primary pericytes are capable of degrading A β 40 in a BACE1-dependent manner

Based on our findings in human post-mortem brain tissue and in isolated microvessels, we hypothesized an early involvement of brain pericytes in enzymatic A β degradation leading to the generation of A β 34 as an intermediate, and a failure of this clearance pathway with advancing disease stages in AD. We moreover observed a positive correlation between A β 34 and A β 40 in isolated human microvessels from non-demented elderly individuals suggesting that A β 40 could be the main substrate for uptake and potential enzymatic degradation to A β 34 at the neurovascular unit. To assess whether pericytes are capable of generating A β 34 in vitro, uptake and degradation of extracellularly applied A β 40 were further

investigated in human primary pericyte cultures. As a first step, expression of the A β uptake receptor, low density lipoprotein receptor-related protein 1 (LRP1), and of the major A β 34 producing enzyme, BACE1, were confirmed by immunocytochemistry and Western blotting (Fig. 4a-b). In the following, human primary pericytes were incubated with varying concentrations (10 μ M, 5 μ M, 2.5 μ M and 1 μ M) of recombinant human A β 40 peptide for different treatment durations (12 h, 24 h, 36 h, 48 h). These experiments revealed a dose and time dependent increase in A β 34 levels both in cell lysates and in cell media (Fig. 4c-d). In order to assess whether A β 34 generation in primary pericytes was dependent on the uptake of extracellular A β 40, cultures were treated with either a generic endocytosis blocker, IPA3, or with a specific LRP1 blocker, receptor associated protein (RAP). Treatment with both compounds significantly reduced the uptake of fluorescently-labeled A β 40 in human primary pericytes (Additional file 3a-b). A β 34 levels in cell lysates were significantly reduced when pericytes had been pre-incubated with IPA3 or RAP before A β 40 treatment (Fig. 4e) thus confirming that internalization of extracellular A β 40 is crucial for A β 34 generation in pericytes. In order to rule out the possibility of an increased de novo synthesis of A β 34 in pericytes upon A β 40 treatment, we further evaluated the source of A β 34 generated in the pericyte culture. For this purpose, pericytes were treated with mouse A β 40 and levels of A β 34 were measured by using either a mid-domain (clone 4G8) or an N-terminal (clone 6E10) anti-amyloid detection antibody. The N-terminal antibody had previously been shown to be human specific whereas the mid-domain antibody is known to detect both human and murine A β isoforms [57]. After treatment with mouse A β 40, only the mid-domain antibody was able to detect the increase in A β 34 levels while the N-terminal, human A β specific, antibody failed to detect any changes (Additional file 3c). The result of this experiment therefore suggested that upon treatment with mouse A β 40, human pericytes predominantly generated mouse A β 34 via degradation of extracellularly applied A β 40. Enzymatic degradation of A β in pericytes was further investigated upon pharmacological inhibition of the major degrading enzyme. Since A β 34 was identified as an intermediate of BACE1-mediated enzymatic degradation and BACE1 expression could be confirmed in human primary pericyte culture, pericytes were treated with varying concentrations (10 μ M, 5 μ M, 2 μ M and 1 μ M) of the BACE1 inhibitor IV, and A β 34 levels were assessed upon BACE 1 inhibition. Treatment of pericytes with inhibitor IV prior to A β 40 treatment led to a dose dependent decrease in A β 34 levels in pericytes (Fig. 4f) supporting the role of BACE1 in A β 34 generation in pericytes. Consequently, our in vitro cell culture results




demonstrate that Aβ34 can be generated as an intermediate of BACE1-mediated enzymatic degradation of internalized Aβ40 in pericytes.

Discussion

The C-terminally truncated Aβ isoform, Aβ34, has been identified as an important intermediate product of enzymatic Aβ degradation clearance. Although, in principle, Aβ34 can be generated via various enzymatic pathways, BACE1 was recently shown to be a major enzyme involved in Aβ34 generation in vivo [30]. In our recently published study, we showed elevated CSF Aβ34

levels in early clinical stages of AD and a correlation of CSF Aβ34 levels with Aβ clearance rates in subjects with evidence of cerebral amyloid deposition [30]. In the present study, we analyzed the distribution of Aβ34 in post-mortem human brain samples to further investigate its role in AD pathology and neurodegenerative disease progression. Our comprehensive histological analysis revealed a unique association of Aβ34 immunoreactivity with pericytes in brain capillaries and a loss of this capillary associated Aβ34 immunoreactivity with advancing disease stages in AD patients. Interestingly, we observed a peak in capillary Aβ34 immunoreactivity in the earlier



Braak stages (stage 2–3) which then dramatically decreased between Braak stages 3 and 4. The correlation of Braak stages with cognitive scores used in clinical practice had been investigated by several previous studies suggesting that individuals with MCI were most likely distributed between Braak stages 2 and 4 [3, 21, 63]. Based on our current data, however, a definitive conclusion whether the observed increase in capillary A β 34 immunoreactivity in the earlier Braak stages indeed represents a histopathological correlate of elevated CSF A β 34 levels detected in the recently published prodromal AD clinical sample [30] cannot be drawn at this point. On the one hand, we were not able to assess CSF A β 34 levels in our post-mortem cohort. On the other hand, the post-mortem neuropathological sample was clinically divided only into two diagnostic categories, i.e. AD dementia and non-demented controls, the latter

including both healthy elderly individuals and non-demented controls meeting the clinical criteria for a mild cognitive impairment. Another limitation of our study sample was the lack of younger individuals and age-matched controls of even earlier Braak stages (Braak stage 0) mainly due to the low prevalence and unavailability of this control group [37]. Analysis of such additional samples may be particularly helpful in clarifying the question whether pericyte mediated A β degradation occurs already at a very early stage in the absence of overt AD pathology, and whether it is upregulated in an age-dependent manner.

In our study, we provided substantial histological and biochemical evidence for an association of A β 34 with brain pericytes. In vitro mechanistic assessments moreover revealed that pericytes can generate A β 34 by uptake and degradation of extracellular A β 40. Nevertheless, the

results of these experiments do not exclude the possibility that A β 34 is generated elsewhere, e.g. in neurons, and ultimately only taken up by pericytes for further degradation. As a major A β source and the primary cell type expressing BACE1 in the brain [5], neurons highly likely represent an alternative source of A β 34 generation in the central nervous system. This assumption is also supported by a previous study reporting intraneuronal A β 34 immunoreactivity [12]. The detection of capillary A β 34 immunoreactivity, however, may in our opinion be better explained by an in situ production of A β 34 in pericytes. Due to its short half-life and its susceptibility to further enzymatic degradation [11, 30], it appears rather unlikely that neuronal A β 34 would reach the microvasculature in sufficient amounts in order to be taken up by brain pericytes. We rather propose that the more stable and more abundant A β isoforms like A β 40 and possibly also A β 42 which were previously shown to be drained along vascular clearance routes [59, 60] are taken up by pericytes and locally degraded to A β 34 at the neurovascular unit. In line with this assumption, our mechanistic studies in human primary pericytes demonstrated that pericytes are fully capable of taking up and degrading A β 40 to A β 34. We did not specifically assess whether A β 42 can also be degraded to A β 34 by pericytes in vitro since the previously reported relative abundance of A β 40 at the vasculature compared to A β 42 [26, 53, 59] and our correlative analyses and findings in the human microvessels would rather be in line with A β 40 being the major A β 34 precursor in vivo. However, earlier studies illustrated that A β 42 is also a substrate of BACE1 [19, 30] hence pericyte-associated A β 34 could be generated via BACE1-mediated degradation of A β 42. Both A β 40 and A β 42 fibrils were reported to induce pericyte death in vitro; nevertheless A β 34 was shown not to aggregate even in high concentrations [11] and did not show any deleterious effects in our pericyte culture experiments (data not shown). Previously, Caillava et al. even suggested a protective role for this isoform since A β 34 treatment lowered the apoptotic cell death in HEK cells in vitro [12]. Considering susceptibility of this isoform to further enzymatic degradation by metalloproteases [12, 30], we suggest that BACE-1 mediated degradation of A β 40 or A β 42 would enhance both enzymatic and vascular clearance by generating more accessible, benign and likely protective against apoptosis, isoform A β 34.

The increase in A β 34 immunoreactivity which we observed in our post-mortem sample may reflect a compensatory upregulation of vascular A β degradation in the early (preclinical or prodromal) stages of AD. As mentioned above, such an upregulation of A β 34-related degradation clearance could provide an explanation for the observed increase in CSF A β 34 levels in patients

with prodromal AD [30]. As an alternative, elevated CSF A β 34 levels might also be explained by an unspecific release of A β 34 by degenerating cells, which in our case would be pericytes. We could not fully address with our cross-sectional correlative postmortem study design, whether the loss of A β 34 immunoreactivity is caused by the physical loss of pericytes during disease progression. The decrease in A β 34+ vessels appeared to be more pronounced than the decrease in the percentage of PDGFR- β + capillaries with advancing disease stages, suggesting in addition to the loss of pericytes, a functional impairment might have contributed to the observed findings. Nevertheless, the robust positive correlation between A β 34 and PDGFR- β immunoreactivity in the brain and levels in our microvessel preparations support that at least partially an early loss of pericytes could be an important factor. In that regard, A β 34 could also represent a sensitive candidate marker reflecting impairments in cerebrovascular pericyte function.

In the present study, we occasionally observed A β 34 immunoreactivity in association with CAA in arterioles and large arterial vessels. However, only a limited number of individuals in our sample set showed CAA pathology, and capillary CAA (capCAA) was completely absent (Additional file 4). Wisniewski et al. previously reported presence of A β fibrils in cerebral vessels associated with pericytes [64]; due to a lack of capillary CAA cases we were unfortunately not able to assess the association between A β 34 and aggregated A β forms in capillaries in our study. In case of arterial CAA, we speculate that A β 34 immunoreactivity in these arteries might be the result of binding of this isoform to deposited vascular amyloid in arterial walls, e.g. upon failed vascular drainage. Alternatively, A β 34 could also be locally generated in CAA-laden vessels, e.g. through the proteolytic cleavage of longer A β isoforms by BACE1 or MMPs [19, 25]. In support of this hypothesis, elevated levels of vascular BACE1 were previously described in CAA-laden arteries [7, 13, 16]. Further studies focusing on CAA and vascular amyloidosis in samples including capCAA will be required to obtain a better understanding of the origin of A β 34 in CAA-affected arteries.

Pericytes have vital roles in vascular development, formation and maintenance of the blood brain barrier (BBB), blood flow regulation as well as in modulating immune reactions in the brain [1, 2, 4, 15, 29]. In addition, it has recently been shown that pericytes can take up extracellular A β 42 via a LRP1/ APOE dependent mechanism in vitro [32]. Pericyte deficiency was shown to worsen AD pathology in transgenic animals with enhanced A β levels in the brain; conversely, pericyte implantation improved clearance of A β and reduced A β deposition [44, 55]. Given their location in the intramural periarterial drainage pathways and their ability to

take up and degrade extracellular A β , pericytes have been implicated to have a role in A β clearance [17, 24]. We have shown, for the first time, an association of these cells with an important intermediate product of A β clearance. Our results are thus in line with the emerging role of pericytes in enzymatic A β degradation in human brain [32]. A failure of the pericyte-mediated A β degradation pathway could result in a progressive loss of vascular A β clearance, enhanced A β 40 accumulation in the vasculature and consecutive impact on parenchymal A β clearance and deposition. The strong inverse association between A β 34 immunoreactivity and tau pathology which we detected in our post-mortem sample suggests that this clearance pathway may have tremendous impact on neurodegenerative processes associated with AD.

Conclusions

In the present study we were able to show a unique association of the A β degradation intermediate A β 34 with brain pericytes in capillaries of non-demented elderly individuals and patients with manifest AD dementia. The observed loss of pericytic A β 34 in AD suggests an early failure of this novel A β clearance pathway at the neuro-vascular unit. Collectively, our findings strengthen the role of the vascular system in early AD and provide further support for a key role of brain pericytes in A β clearance and disease pathogenesis [30, 54].

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s40478-019-0846-8>.

Additional file 1. Primary antibodies used in immunofluorescence (IF), immunocytochemistry (ICC) and western blot (WB).

Additional file 2. Additional A β 34-PDGFR- β immunostainings. ThioS staining. Vessel density quantification.

Additional file 3. Additional in vitro pericyte culture results.

Additional file 4. Cerebral Amyloid Angiopathy (CAA) quantification.

Abbreviations

AD: Alzheimer's disease; ANOVA: Analysis of variance; APOE: Apolipoprotein E; APP: Amyloid precursor protein; A β : Amyloid-beta; BACE1: β -site APP-cleaving enzyme; CAA: Congophilic amyloid angiopathy; CERAD: Consortium to Establish a Registry for Alzheimer's Disease; CSF: Cerebrospinal fluid; ELISA: Enzyme-linked immunosorbent assay; GFAP: Glial fibrillary acidic protein; HBSS: Hank's balanced salt solution; HRP: Horseradish peroxidase; IPA3: 1,1'-Dithiodi-2-naphthol; LRP1: Lipoprotein receptor-related protein; MCI: Mild cognitive impairment; MMP: Matrix metalloprotease; MSD: Meso scale discovery; NBB: Netherlands Brain Bank; NDCNTRL: Non-demented control; NFT: Neurofibrillary tangle; PBS: Phosphate-buffered saline; PDGFR- β : Platelet derived growth factor receptor beta; PFA: Paraformaldehyde; RAP: Receptor associated protein

Acknowledgements

Thanks to the Velux Stiftung, Brain@McGill, the Natural Sciences and Engineering Research Council of Canada, the Canadian Consortium on Neurodegeneration in Aging, and the Canadian Institute of Health Research (MOP-133411) for support awarded to G.M., C.H., L.K., and F.L.. GM holds both

a Canada Research Chair in Molecular Pharmacology and a Canada Foundation for Innovation (CFI) grant and is grateful to the CFI for infrastructure support.

Authors' contributions

TK designed and performed experiments, analyzed data, prepared the figures, and wrote the manuscript. ASi, ASH, SR, and FL designed and performed experiments, analyzed data, and helped writing the manuscript. RMN and CH, designed experiments, supervised the project and helped writing the manuscript. GM and LK designed experiments, analyzed data, supervised the project and wrote the manuscript. All authors have approved the final version of the manuscript.

Funding

This study was financed by Velux Stiftung (Project No 993a).

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Post-mortem samples were collected from donors with a written informed consent for a brain autopsy and the use of the material for research purposes was obtained by the Netherlands Brain Bank.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Institute for Regenerative Medicine, University of Zurich, 8952 Schlieren, Switzerland. ²Present Address: Department of Chemistry University of Cologne, Institute of Biochemistry, 50674 Cologne, Germany. ³Department of Pharmacology & Therapeutics and Integrated Program in Neuroscience, McGill University, Montreal, QC H3G 1Y6, Canada. ⁴Neurimmune, 8952 Schlieren, Switzerland. ⁵F. Hoffmann-La Roche Ltd., Roche Pharma Research & Early Development, 4070 Basel, Switzerland.

Received: 11 November 2019 Accepted: 13 November 2019

Published online: 03 December 2019

References

- Armulik A, Genové G, Betsholtz C (2011) Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev Cell* 21:193–215. <https://doi.org/10.1016/j.devcel.2011.07.001>
- Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, He L, Norlin J, Lindblom P, Strittmatter K, Johansson BR, Betsholtz C (2010) Pericytes regulate the blood-brain barrier. *Nature* 468:557–561. <https://doi.org/10.1038/nature09522>
- Bancher C, Braak H, Fischer P, Jellinger KA (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. *Neurosci Lett* 162:179–182. [https://doi.org/10.1016/0304-3940\(93\)90590-H](https://doi.org/10.1016/0304-3940(93)90590-H)
- Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. *Neuron* 68:409–427. <https://doi.org/10.1016/j.neuron.2010.09.043>
- Bigl M, Apelt J, Luschekina EA, Lange-Dohna C, Rossner S, Schliebs R (2000) Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. *Neurosci Lett* 292:107–110. [https://doi.org/10.1016/S0304-3940\(00\)01452-X](https://doi.org/10.1016/S0304-3940(00)01452-X)
- Boulay A-C, Saubaméa B, Declèves X, Cohen-Salmon M (2015) Purification of mouse brain vessels. *JoVE J Vis Exp* 53208. <https://doi.org/10.3791/53208>
- Bourassa P, Tremblay C, Schneider JA, Bennett DA, Calon F (2019) Beta-amyloid pathology in human brain microvessel extracts from the parietal cortex: relation with cerebral amyloid angiopathy and Alzheimer's disease. *Acta Neuropathol (Berl)* 137:801–823. <https://doi.org/10.1007/s00401-019-01967-4>

8. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Tredici KD (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol (Berl)* 112:389–404. <https://doi.org/10.1007/s00401-006-0127-z>
9. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging* 16:271–278. [https://doi.org/10.1016/0197-4580\(95\)00021-6](https://doi.org/10.1016/0197-4580(95)00021-6)
10. Brzica H, Abdullahi W, Reilly BG, Ronaldson PT (2018) A simple and reproducible method to prepare membrane samples from freshly isolated rat brain microvessels. *JoVE J Vis Exp*:e57698. <https://doi.org/10.3791/57698>
11. Cabrera E, Mathews P, Mezhericher E, Beach TG, Deng J, Neubert TA, Rostagno A, Ghiso J (2018) A β truncated species: implications for brain clearance mechanisms and amyloid plaque deposition. *Biochim Biophys Acta* 1864:208–225. <https://doi.org/10.1016/j.bbdis.2017.07.005>
12. Caillava C, Ranaldi S, Lauritzen I, Bauer C, Fareh J, Abraham J-D, Checler F (2014) Study on A β 34 biology and detection in transgenic mice brains. *Neurobiol Aging* 35:1570–1581. <https://doi.org/10.1016/j.neurobiolaging.2014.01.011>
13. Cheng X, He P, Yao H, Dong Q, Li R, Shen Y (2014) Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy. *Neurology* 82:1707–1715. <https://doi.org/10.1212/WNL.0000000000000403>
14. Chow VW, Mattson MP, Wong PC, Gleichmann M (2010) An overview of APP processing enzymes and products. *NeuroMolecular Med* 12:1–12. <https://doi.org/10.1007/s12017-009-8104-z>
15. Dalkara T, Gursay-Ozdemir Y, Yemisci M (2011) Brain microvascular pericytes in health and disease. *Acta Neuropathol (Berl)* 122:1. <https://doi.org/10.1007/s00401-011-0847-6>
16. Devraj K, Poznanovic S, Spahn C, Schwall G, Harter PN, Mittelbronn M, Antoniello K, Paganetti P, Muhs A, Heilemann M, Hawkins RA, Schratzenholz A, Liebnert S (2016) BACE-1 is expressed in the blood–brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease. *J Cereb Blood Flow Metab* 36:1281–1294. <https://doi.org/10.1177/0271678X15606463>
17. Diem AK, MacGregor Sharp M, Gatherer M, Bressloff NW, Carare RO, Richardson G (2017) Arterial pulsations cannot drive intramural periaarterial drainage: significance for A β drainage. *Front Neurosci* 11. <https://doi.org/10.3389/fnins.2017.00475>
18. Dunys J, Valverde A, Checler F (2018) Are N- and C-terminally truncated A β species key pathological triggers in Alzheimer's disease? *J Biol Chem* 293:15419–15428. <https://doi.org/10.1074/jbc.R118.003999>
19. Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, Willem M, Westmeyer G, Bode W, Walter J, Haass C (2003) Identification of a β -Secretase activity, which truncates amyloid β -peptide after its Presenilin-dependent generation. *J Biol Chem* 278:5531–5538. <https://doi.org/10.1074/jbc.M211485200>
20. Grandjean J, Derungs R, Kulic L, Welt T, Henkelman M, Nitsch RM, Rudin M (2016) Complex interplay between brain function and structure during cerebral amyloidosis in APP transgenic mouse strains revealed by multi-parametric MRI comparison. *NeuroImage* 134:1–11. <https://doi.org/10.1016/j.neuroimage.2016.03.042>
21. Grober E, Dickson D, Sliwinski MJ, Buschke H, Katz M, Crystal H, Lipton RB (1999) Memory and mental status correlates of modified Braak staging. *Neurobiol Aging* 20:573–579. [https://doi.org/10.1016/S0197-4580\(99\)00063-9](https://doi.org/10.1016/S0197-4580(99)00063-9)
22. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. *J Biol Chem* 261:6084–6089
23. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, Zlokovic BV (2016) Accelerated pericyte degeneration and blood–brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. *J Cereb Blood Flow Metab* 36:216–227. <https://doi.org/10.1038/jcbfm.2015.44>
24. Hawkes CA, Härtig W, Kacza J, Schliebs R, Weller RO, Nicoll JA, Carare RO (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. *Acta Neuropathol (Berl)* 121:431–443. <https://doi.org/10.1007/s00401-011-0801-7>
25. Hernandez-Guillamon M, Mawhirt S, Blais S, Montaner J, Neubert TA, Rostagno A, Ghiso J (2015) Sequential amyloid- β degradation by the matrix Metalloproteinases MMP-2 and MMP-9. *J Biol Chem* 290:15078–15091. <https://doi.org/10.1074/jbc.M114.610931>
26. Herzig MC, Van Nostrand WE, Jucker M (2006) Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. *Brain Pathol Zurich Switz* 16:40–54
27. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ (2012) National Institute on Aging–Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc* 8:1–13. <https://doi.org/10.1016/j.jalz.2011.10.007>
28. Kakuda N, Miyasaka T, Iwasaki N, Nirasawa T, Wada-Kakuda S, Takahashi-Fujigasaki J, Murayama S, Ihara Y, Ikegawa M (2017) Distinct deposition of amyloid- β species in brains with Alzheimer's disease pathology visualized with MALDI imaging mass spectrometry. *Acta Neuropathol Commun* 5:73. <https://doi.org/10.1186/s40478-017-0477-x>
29. Krueger M, Bechmann I (2010) CNS pericytes: concepts, misconceptions, and a way out. *Glia* 58:1–10. <https://doi.org/10.1002/glia.20898>
30. Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G (2019) A β 34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. *Nat Commun* 10:2240. <https://doi.org/10.1038/s41467-019-10152-w>
31. Lindahl P, Johansson BR, Leveen P, Betsholtz C (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. *Science* 277:242–245. <https://doi.org/10.1126/science.277.5323.242>
32. Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV (2018) Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid- β 42 by LRP1-dependent apolipoprotein E isoform-specific mechanism. *Mol Neurodegener* 13:57. <https://doi.org/10.1186/s13024-018-0286-0>
33. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci U S A* 82:4245–4249. <https://doi.org/10.1073/pnas.82.12.4245>
34. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS β -amyloid in Alzheimer's disease. *Science* 330:1774–1774. <https://doi.org/10.1126/science.1197623>
35. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R (2005) Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. *Biochemistry (Mosc)* 44:10810–10821. <https://doi.org/10.1021/bi0508237>
36. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer's Association (2012) National Institute on Aging–Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol (Berl)* 123:1–11. <https://doi.org/10.1007/s00401-011-0910-3>
37. Nolan M, Troakes C, King A, Bodi I, Al-Sarraj S (2015) Control tissue in brain banking: the importance of thorough neuropathological assessment. *J Neural Transm* 122:949–956. <https://doi.org/10.1007/s00702-015-1376-6>
38. Oliveira VC, Carrara RCV, Simoes DLC, Saggiaro FP, Carlotti CG, Covas DT, Neder L (2010) Sudan Black B treatment reduces autofluorescence and improves resolution of in situ hybridization specific fluorescent signals of brain sections. *Histol Histopathol* 25:1017–1024. <https://doi.org/10.14670/HH-25.1017>
39. Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S, Lendahl U, Multhaup G, Lundkvist J (2014) Characterization of intermediate steps in amyloid Beta (A β) production under near-native conditions. *J Biol Chem* 289:1540–1550. <https://doi.org/10.1074/jbc.M113.498246>
40. Portelius E, Bogdanovic N, Gustavsson MK, Volkman I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K (2010) Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol (Berl)* 120:185–193. <https://doi.org/10.1007/s00401-010-0690-1>
41. Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, Demattos RB, Racke MM, Zetterberg H, May PC, Blennow K (2014) β -site amyloid precursor protein-cleaving enzyme 1 (BACE1) inhibitor treatment induces A β 5-X peptides through alternative amyloid precursor protein cleavage. *Alzheimers Res Ther* 6. <https://doi.org/10.1186/s13195-014-0075-0>
42. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K (2006) Determination of beta-amyloid peptide signatures in cerebrospinal fluid

- using immunoprecipitation-mass spectrometry. *J Proteome Res* 5:1010–1016. <https://doi.org/10.1021/pr050475v>
43. Reinert J, Richard BC, Klafki HW, Friedrich B, Bayer TA, Wiltfang J, Kovacs GG, Ingelsson M, Lannfelt L, Paetau A, Bergquist J, Wirths O (2016) Deposition of C-terminally truncated A β species A β 37 and A β 39 in Alzheimer's disease and transgenic mouse models. *Acta Neuropathol Commun* 4:24. <https://doi.org/10.1186/s40478-016-0294-7>
 44. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, Zlokovic BV (2013) Pericyte loss influences Alzheimer-like neurodegeneration in mice. *Nat Commun* 4:2932. <https://doi.org/10.1038/ncomms3932>
 45. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. *Neurosci Lett* 215:173–176. [https://doi.org/10.1016/0304-3940\(96\)12970-0](https://doi.org/10.1016/0304-3940(96)12970-0)
 46. Schönherr C, Bien J, Isbert S, Wichert R, Prox J, Altmepfen H, Kumar S, Walter J, Lichtenthaler SF, Weggen S, Glatzel M, Becker-Paulky C, Pietrzik CU (2016) Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site. *Mol Neurodegener* 11:19. <https://doi.org/10.1186/s13024-016-0084-5>
 47. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* 8:595–608. <https://doi.org/10.15252/emmm.201606210>
 48. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic BV (2013) Deficiency in mural vascular cells coincides with blood–brain barrier disruption in Alzheimer's disease. *Brain Pathol* 23:303–310. <https://doi.org/10.1111/bpa.12004>
 49. Sevalle J, Amoyel A, Robert P, Fournié-Zaluski M-C, Roques B, Checler F (2009) Aminopeptidase A contributes to the N-terminal truncation of amyloid β -peptide. *J Neurochem* 109:248–256. <https://doi.org/10.1111/j.1471-4159.2009.05950.x>
 50. Shi X-P, Tugusheva K, Bruce JE, Lucka A, Wu G-X, Chen-Dodson E, Price E, Li Y, Xu M, Huang Q, Sardana MK, Hazuda DJ (2003) β -Secretase cleavage at amino acid residue 34 in the amyloid β peptide is dependent upon γ -Secretase activity. *J Biol Chem* 278:21286–21294. <https://doi.org/10.1074/jbc.M209859200>
 51. Söddner CA, Sticht H, Horn AHC (2017) Role of the N-terminus for the stability of an amyloid- β fibril with three-fold symmetry. *PLoS One* 12: e0186347. <https://doi.org/10.1371/journal.pone.0186347>
 52. Stine WB, Jungbauer L, Yu C, LaDu MJ (2011) Preparing synthetic A β in different aggregation states. *Methods Mol Biol Clifton NJ* 670:13–32. https://doi.org/10.1007/978-1-60761-744-0_2
 53. Suzuki N, Iwatsubo T, Odaka A, Ishibashi Y, Kitada C, Ihara Y (1994) High tissue content of soluble beta 1–40 is linked to cerebral amyloid angiopathy. *Am J Pathol* 145:452–460
 54. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Salnan RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, González HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O'Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Román GC, Hamel E, Seshadri S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV (2019) Vascular dysfunction—the disregarded partner of Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc* 15:158–167. <https://doi.org/10.1016/j.jalz.2018.07.222>
 55. Tachibana M, Yamazaki Y, Liu C-C, Bu G, Kanekiyo T (2018) Pericyte implantation in the brain enhances cerebral blood flow and reduces amyloid- β pathology in amyloid model mice. *Exp Neurol* 300:13–21. <https://doi.org/10.1016/j.expneurol.2017.10.023>
 56. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y (2009) gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. *J Neurosci* 29:13042–13052. <https://doi.org/10.1523/JNEUROSCI.2362-09.2009>
 57. Teich AF, Patel M, Arancio O (2013) A reliable way to detect endogenous murine β -amyloid. *PLoS One* 8. <https://doi.org/10.1371/journal.pone.0055647>
 58. Thal DR, Walter J, Saido TC, Fändrich M (2015) Neuropathology and biochemistry of A β and its aggregates in Alzheimer's disease. *Acta Neuropathol (Berl)* 129:167–182. <https://doi.org/10.1007/s00401-014-1375-y>
 59. Weller RO, Massey A, Newman TA, Hutchings M, Kuo Y-M, Roher AE (1998) Cerebral amyloid Angiopathy: amyloid β accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. *Am J Pathol* 153:725–733. [https://doi.org/10.1016/S0002-9440\(10\)65616-7](https://doi.org/10.1016/S0002-9440(10)65616-7)
 60. Weller RO, Preston SD, Subash M, Carare RO (2009) Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. *Alzheimers Res Ther* 1:6. <https://doi.org/10.1186/alzrt6>
 61. Wesén E, Jeffries GDM, Matson Dzebo M, Esbjörner EK (2017) Endocytic uptake of monomeric amyloid- β peptides is clathrin- and dynamin-independent and results in selective accumulation of A β (1–42) compared to A β (1–40). *Sci Rep* 7. <https://doi.org/10.1038/s41598-017-02227-9>
 62. Wildburger NC, Esparza TJ, LeDuc RD, Fellers RT, Thomas PM, Cairns NJ, Kelleher NL, Bateman RJ, Brody DL (2017) Diversity of amyloid-beta proteoforms in the Alzheimer's disease brain. *Sci Rep* 7:9520. <https://doi.org/10.1038/s41598-017-10422-x>
 63. Wischik CM, Harrington CR, Storey JMD (2014) Tau-aggregation inhibitor therapy for Alzheimer's disease. *Biochem Pharmacol* 88:529–539. <https://doi.org/10.1016/j.bcp.2013.12.008>
 64. Wisniewski HM, Wegiel J, Wang KC, Lach B (1992) Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease. *Acta Neuropathol (Berl)* 84:117–127. <https://doi.org/10.1007/BF00311383>
 65. Yousif S, Marie-Claire C, Roux F, Scherrmann J-M, Declèves X (2007) Expression of drug transporters at the blood–brain barrier using an optimized isolated rat brain microvessel strategy. *Brain Res* 1134:1–11. <https://doi.org/10.1016/j.brainres.2006.11.089>
 66. Zhang Y, Thompson R, Zhang H, Xu H (2011) APP processing in Alzheimer's disease. *Mol Brain* 4:3

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

